全文获取类型
收费全文 | 167篇 |
免费 | 16篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 5篇 |
妇产科学 | 2篇 |
基础医学 | 26篇 |
临床医学 | 4篇 |
内科学 | 46篇 |
皮肤病学 | 22篇 |
神经病学 | 4篇 |
特种医学 | 3篇 |
外科学 | 12篇 |
综合类 | 1篇 |
药学 | 3篇 |
肿瘤学 | 48篇 |
出版年
2024年 | 1篇 |
2023年 | 3篇 |
2022年 | 2篇 |
2021年 | 5篇 |
2020年 | 1篇 |
2019年 | 2篇 |
2018年 | 3篇 |
2017年 | 2篇 |
2016年 | 1篇 |
2015年 | 6篇 |
2014年 | 10篇 |
2013年 | 7篇 |
2012年 | 12篇 |
2011年 | 12篇 |
2010年 | 6篇 |
2009年 | 3篇 |
2008年 | 5篇 |
2007年 | 7篇 |
2006年 | 7篇 |
2005年 | 10篇 |
2004年 | 4篇 |
2003年 | 7篇 |
2002年 | 7篇 |
2001年 | 9篇 |
2000年 | 5篇 |
1999年 | 6篇 |
1998年 | 3篇 |
1997年 | 3篇 |
1996年 | 3篇 |
1995年 | 1篇 |
1994年 | 2篇 |
1992年 | 6篇 |
1991年 | 3篇 |
1990年 | 3篇 |
1989年 | 3篇 |
1988年 | 1篇 |
1987年 | 3篇 |
1986年 | 2篇 |
1985年 | 3篇 |
1984年 | 1篇 |
1983年 | 2篇 |
1982年 | 1篇 |
排序方式: 共有183条查询结果,搜索用时 15 毫秒
71.
Romano Demicheli Elia Biganzoli Ilaria Ardoino Patrizia Boracchi Danila Coradini Marco Greco Angela Moliterni Milvia Zambetti Pinuccia Valagussa Isaac D. Gukas Gianni Bonadonna 《Cancer science》2010,101(3):826-830
(Cancer Sci 2010; 101: 826–830) The purpose was to ascertain whether the recurrence risk patterns for patients with estrogen receptor (ER)‐positive (P) and ER‐negative (N) breast cancer support the ER‐related clinical divergence suggested by the observed different mortality patterns and gene expression profiles. Both recurrence and death were considered in a series of 771 patients undergoing mastectomy. ER status was available for 539 patients. The hazard rates for recurrence and mortality throughout 15 years of follow‐up were assessed. The recurrence dynamics displays a bimodal pattern for both ERP and ERN tumors with comparable peak timings. The two curves cross during the 3rd year. By contrast, the mortality dynamics are definitely different for ERP and ERN tumors: during the early follow‐up period ERN patients have their highest mortality risk, while ERP patients have their lowest mortality risk. The two curves cross during the 5th year. In spite of the different mortality dynamics, the recurrence dynamics do not demonstrate a major distinction in timing between ERP and ERN breast cancers, suggesting that the metastasis development process following mastectomy is apparently similar for both ER categories. The observed differences in the mortality risk are plausibly attributable to ER‐related factors influencing the clinical course from recurrence to death. These clinical findings apparently contradict the occurrence of two different types of breast cancer, notwithstanding the distinct epidemiological, clinical, and molecular features linked to ERP and ERN tumors, although ER levels may concur to establish the event risk levels. 相似文献
72.
Blue rubber bleb nevus syndrome: late onset in a patient with cutaneous,neurological, and gastrointestinal involvement
下载免费PDF全文
![点击此处可从《International journal of dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
73.
Multicentric study on the diagnosis of Fabry's disease using angiokeratoma biopsy registries
下载免费PDF全文
![点击此处可从《International journal of dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Samantha Vernaschi Kelmann MD Caio Robledo D'Angioli Costa Quaio MD Rachel Sayuri Honjo MD PhD Debora Romeo Bertola MD PhD Nilton Salles Rosa Neto MD PhD Charles Marques Lourenço MD PhD Vânia d'Almeida MD PhD Rute Facchini Lellis MD PhD Maria Cecília Rivitti‐Machado MD PhD Milvia Maria Simões e Silva Enokihara MD PhD Nilceo S Michalany MD PhD Chong Ae Kim MD PhD 《International journal of dermatology》2015,54(6):e241-e244
74.
75.
Stefania Colantuono Milica Mitrevski Baoran Yang Julia Tola Maurizio Carlesimo Giuseppe M. De Sanctis Massimo Fiorilli Milvia Casato Marcella Visentini 《Clinical rheumatology》2017,36(3):617-623
This study aims to evaluate the efficacy and safety of repeated treatments with low-dose rituximab for relapsing mixed cryoglobulinemia vasculitis. Thirty-seven patients with mixed cryoglobulinemia vasculitis refractory to standard of care treatment, 34 of which were HCV-positive, were treated with rituximab at the reduced dosage of 250 mg/m2 given twice 1 week apart per cycle. Thirty patients (81%) achieved a clinical response; 5 of them remain in remission, 3 were lost to follow-up or died, and 22 relapsed after a mean of 15.7 months. Eleven relapsers were retreated with one (6 patients), 2 (3 patients), or 3 (2 patients) additional rituximab cycles given at each relapse. Clinical and laboratory efficacy and side effects of long-term treatment were evaluated. Clinical response to retreatment was 91% (10/11) at the first relapse, 80% (4/5) at the second relapse, and 100% (2/2) at the third relapse. The mean (±SD) time to relapse was 17.1 ± 14.1 months in 30 patients who were treated with only one cycle (from first cycle to the first relapse) and 45.7 ± 30.6 months (from first cycle to the last observed relapse) in 11 patients treated with 2 or more cycles (p = 0.0037). Severe adverse reactions occurred in 3 patients, in 2 of whom at the first cycle. Our results suggest that repeated treatment of relapsing mixed cryoglobulinemia with a low-dose rituximab regimen is efficacious, safe, and cost-effective for the long-term management of this disorder. 相似文献
76.
77.
78.
M Zambetti L Gianni A Escobedo P Pizzetti G B Spatti G Bonadonna 《American journal of clinical oncology》1989,12(2):118-122
Between August 1982 and October 1986, the feasibility and activity of five cycles of intraperitoneal (i.p.) cisplatin (CDDP) (90 mg/m2 in 6 h dwelling) and i.v. cyclophosphamide (600 mg/m2) were studied in 24 previously untreated patients with ovarian carcinoma having small or no residual disease after cytoreductive surgery. Six patients (25%) had local complications requiring catheter removal before the end of therapy. Fifteen of the 21 patients (71%) evaluable for activity achieved or maintained a pathologic complete remission. The median disease-free survival was 29+ months (range 18-58+ months). Three patients with tumor progression (two patients previously without evidence of disease, and one patient with minimal residual disease), and three partial responders were documented by laparotomy at the end of therapy. Two patients who achieved pathologic complete response relapsed at 20 and 36 months. All treatment failures (eight cases, 38%) occurred in the peritoneal cavity. Since patients were selected for having the most favorable tumor characteristics to benefit from i.p. treatment, our findings may cast some doubt on the actual contribution of i.p. CDDP at a dose of 90 mg/m2 in the treatment of patients with ovarian carcinoma and small residual disease in the peritoneal cavity. 相似文献
79.
80.